Neogenomics Income Statement (2010-2026) | NEO

Frequency:

Period:

1Y 3Y 5Y 7Y 10Y All

Values in:

Download Data

Income Statement	Sep2021	Dec2021	Mar2022	Jun2022	Sep2022	Dec2022	Mar2023	Jun2023	Sep2023	Dec2023	Mar2024	Jun2024	Sep2024	Dec2024	Mar2025	Jun2025	Sep2025	Dec2025	Mar2026	Jun2026
Revenue & cost
Revenue (Quarter)	121.34M	125.73M	117.17M	125.07M	128.78M	138.71M	137.22M	146.92M	151.95M	155.55M	156.24M	164.50M	167.82M	172.00M	168.03M	181.33M	187.80M	190.17M	186.67M	201.66M
Cost of Revenue (Quarter)	74.10M	80.47M	78.94M	81.13M	79.89M	81.88M	82.41M	87.03M	89.64M	87.96M	90.77M	92.01M	92.94M	94.74M	94.79M	104.07M	107.35M	106.83M	105.81M	109.78M
Gross Profit (Quarter)	47.24M	45.26M	38.23M	43.95M	48.89M	56.83M	54.81M	59.89M	62.31M	67.59M	65.47M	72.49M	74.88M	77.26M	73.25M	77.26M	80.45M	83.34M	80.86M	91.88M
Operating items
Research & Development (Quarter)	15.70M	15.92M	16.30M	17.07M	16.81M	17.14M	16.26M	18.90M	17.61M	18.07M	20.22M	21.68M	20.41M	22.34M	22.68M	24.07M	21.81M	23.44M	23.83M	27.27M
Selling, General & Administrative (Quarter)	63.84M	62.39M	66.25M	57.95M	64.28M	54.88M	61.55M	60.31M	61.49M	59.76M	65.80M	63.33M	66.97M	63.64M	68.21M	71.75M	69.87M	63.51M	65.74M	63.61M
Restructuring Costs (Quarter)						4.52M	4.68M	3.07M	2.12M	1.21M	2.40M	1.54M	1.01M	1.71M
Other Operating Expenses (Quarter)	7.41M	8.51M	7.71M	8.63M	7.31M	6.67M	7.39M	7.50M	5.29M	7.13M	7.62M	7.89M	7.68M	7.97M	10.18M	29.06M	15.78M	9.80M	9.53M	10.76M
Operating Expenses (Quarter)	86.95M	86.82M	90.26M	83.65M	88.40M	83.21M	89.89M	89.78M	86.51M	86.16M	96.04M	94.44M	96.08M	95.66M	101.07M	124.89M	107.46M	96.76M	99.11M	101.65M
Operating Income (Quarter)	-39.71M	-41.57M	-52.03M	-39.70M	-39.51M	-26.38M	-35.07M	-29.89M	-24.20M	-18.57M	-30.57M	-21.94M	-21.20M	-18.40M	-27.82M	-47.63M	-27.01M	-13.41M	-18.24M	-9.77M
EBIT (Quarter)	-39.71M	-41.57M	-52.03M	-39.70M	-39.51M	-26.38M	-35.07M	-29.89M	-24.20M	-18.57M	-30.57M	-21.94M	-21.20M	-18.40M	-27.82M	-47.63M	-27.01M	-13.41M	-18.24M	-9.77M
Non-operating items
Non Operating Investment Income (Quarter)	17.75M
Interest & Investment Income (Quarter)			-2.37M	-1.05M			1.06M	0.26M	4.53M	4.84M	0.34M	0.31M	4.67M	4.33M	0.15M	2.26M	1.56M	1.52M	1.27M	1.21M
Other Non Operating Income (Quarter)	0.09M	-0.93M	0.17M	-0.41M	0.03M	-0.00M	-0.11M	0.73M	-0.10M	0.12M	-0.26M	-0.00M	0.32M	-0.43M	0.07M	0.48M	-0.34M	0.08M	-0.01M	11.18M
Non Operating Income (Quarter)
Net income details
EBT (Quarter)	-23.17M	-44.20M	-53.16M	-41.03M	-39.62M	-25.52M	-33.72M	-26.64M	-21.45M	-15.29M	-27.68M	-19.02M	-17.85M	-16.13M	-25.66M	-45.82M	-26.39M	-12.41M	-17.58M	1.83M
Tax Provisions (Quarter)	-2.82M	-2.44M	-3.75M	-5.73M	-2.77M	-2.84M	-2.92M	-2.31M	-2.94M	-0.96M	-0.62M	-0.38M	-0.15M	-0.80M	0.27M	-0.72M	0.74M	-2.52M	-0.47M	-0.41M
Profit After Tax (Quarter)	-20.35M	-41.76M	-49.41M	-35.30M	-36.85M	-22.69M	-30.80M	-24.33M	-18.52M	-14.33M	-27.06M	-18.64M	-17.70M	-15.32M	-25.92M	-45.09M	-27.13M	-9.88M	-17.11M	2.24M
Income from Continuing Operations (Quarter)	-20.35M	-41.76M	-49.41M	-35.30M	-36.85M	-22.69M	-30.80M	-24.33M	-18.52M	-14.33M	-27.06M	-18.64M	-17.70M	-15.32M	-25.92M	-45.09M	-27.13M	-9.88M	-17.11M	2.24M
Consolidated Net Income (Quarter)	-20.35M	-41.76M	-49.41M	-35.30M	-36.85M	-22.69M	-30.80M	-24.33M	-18.52M	-14.33M	-27.06M	-18.64M	-17.70M	-15.32M	-25.92M	-45.09M	-27.13M	-9.88M	-17.11M	2.24M
Income towards Parent Company (Quarter)	-20.35M	-41.76M	-49.41M	-35.30M	-36.85M	-22.69M	-30.80M	-24.33M	-18.52M	-14.33M	-27.06M	-18.64M	-17.70M	-15.32M	-25.92M	-45.09M	-27.13M	-9.88M	-17.11M	2.24M
Preferred Dividend Payments (Quarter)
Net Income towards Common Stockholders (Quarter)	-20.35M	-41.76M	-49.41M	-35.30M	-36.85M	-22.69M	-30.80M	-24.33M	-18.52M	-14.33M	-27.06M	-18.64M	-17.70M	-15.32M	-25.92M	-45.09M	-27.13M	-9.88M	-17.11M	2.24M
Additional items
EPS (Basic) (Quarter)	-0.17	-0.35	-0.40	-0.28	-0.30	-0.18	-0.25	-0.19	-0.15	-0.11	-0.21	-0.15	-0.14	-0.12	-0.20	-0.35	-0.21	-0.08	-0.13	0.02
EPS (Diluted) (Quarter)	-0.17	-0.35	-0.40	-0.28	-0.30	-0.18	-0.25	-0.19	-0.15	-0.11	-0.21	-0.15	-0.14	-0.12	-0.20	-0.35	-0.21	-0.08	-0.13	0.02
Shares Outstanding (Quarter)	122.56M	119.96M	123.63M	124.07M	124.42M	124.22M	125.03M	125.36M	125.69M	125.50M	126.11M	126.41M	126.95M	126.66M	127.38M	127.95M	128.41M	128.10M	129.17M	129.63M
Shares Outstanding (Diluted) (Quarter)	122.56M	119.96M	123.63M	124.07M	124.42M	124.22M	125.03M	125.36M	125.69M	125.50M	126.11M	126.41M	126.95M	126.66M	127.38M	127.95M	128.41M	128.10M	129.17M	130.83M
Shares Outstanding (Entity) (Quarter)	123.22M	124.11M	124.72M	125.68M	126.56M	126.91M	127.20M	127.14M	127.26M	127.37M	127.43M	127.85M	128.06M	128.15M	128.36M	128.68M	128.89M	128.99M	129.65M	130.30M
EBITDA (Quarter)	-39.71M	-41.57M	-52.03M	-39.70M	-39.51M	-26.38M	-35.07M	-29.89M	-24.20M	-18.57M	-30.57M	-21.94M	-21.20M	-18.40M	-27.82M	-47.63M	-27.01M	-13.41M	-18.24M	-9.77M
Interest Expenses (Quarter)	33.80M	1.27M	33.48M	33.55M	33.55M	5.21M	32.76M	32.76M	32.76M	-1.85M	32.76M	32.76M	32.76M	4.01M	32.76M	29.98M	29.98M	0.60M	29.53M	29.53M
Tax Rate (Quarter)	12.18%	5.53%	7.06%	13.96%	7.00%	11.12%	8.67%	8.67%	13.68%	6.28%	2.24%	1.97%	0.84%	4.99%	-1.04%	1.58%	-2.80%	20.35%	2.69%	-22.56%

Research Tools

Developers

Neogenomics Income Statement (2010-2026) | NEO

Research Tools

Developers

Neogenomics Income Statement (2010-2026) | NEO

Create an account

Sign In

Reset Password